Business Context and Reporting Period
This Form 8-K Current Report was filed by Skye Bioscience, Inc. on March 4, 2024, covering events that occurred on February 29, 2024. The filing primarily addresses changes to the composition of the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Annual Cash Retainer: $40,000 for Board service.
- Committee Retainers: $2,500 for the Nominating and Corporate Governance Committee; $3,500 for the Compensation Committee.
- Equity Grant: Option to purchase 40,000 shares of common stock, vesting over one year in equal monthly installments.
Material Changes
The Board of Directors underwent the following changes effective February 29, 2024:
- Board Expansion: The authorized size of the Board increased from seven to eight members.
- Appointment: Annalisa Jenkins, M.B.B.S., F.R.C.P., was appointed as a new director and assigned to the Nominating and Corporate Governance Committee and the Compensation Committee.
- Resignation: Margaret Dalesandro, Ph.D., announced her intent to resign from the Board and all committee memberships (Nominating and Corporate Governance, Audit, and Compensation), effective August 1, 2024.
Outlook, Risks, and Management Commentary
Management confirmed that Dr. Dalesandro's resignation is not the result of any disagreement with the Company regarding operations, policies, or practices. No specific business outlook, risk factors, or contingencies were disclosed in this report beyond the standard indemnification agreement entered into by the new director.
Investor Verification Checklist
- Verify the effective date of Dr. Dalesandro's resignation (August 1, 2024) and its impact on committee quorum.
- Review the vesting schedule for the 40,000 share option granted to Dr. Jenkins.
- Confirm the total annual cash compensation for the new director ($46,000).
- Check for any subsequent filings regarding the election of Dr. Jenkins at the next shareholder meeting.